These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 10770186

  • 1. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [Abstract] [Full Text] [Related]

  • 2. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM.
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 4. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P.
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 6. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P, Morange-Ramos I, Cogne M, Jaquet P.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [Abstract] [Full Text] [Related]

  • 7. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
    Shimatsu A, Nakamura A, Takahashi Y, Fujio S, Satoh F, Tahara S, Nishioka H, Takano K, Yamashita M, Arima H, Tominaga A, Tateishi S, Matsushita Y.
    Endocr J; 2021 Jul 28; 68(7):791-805. PubMed ID: 33692246
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF, Liang D, Zhong LY.
    Chin Med J (Engl); 2012 Aug 28; 125(15):2758-63. PubMed ID: 22931988
    [Abstract] [Full Text] [Related]

  • 9. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, Jaquet P.
    J Clin Endocrinol Metab; 1988 Mar 28; 66(3):636-9. PubMed ID: 2895119
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec 28; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 11. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
    Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G.
    Thyroid; 2012 Oct 28; 22(10):1076-9. PubMed ID: 22947349
    [Abstract] [Full Text] [Related]

  • 12. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul 28; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 13. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P, Díez JJ.
    J Endocrinol Invest; 1998 Dec 28; 21(11):775-8. PubMed ID: 9972679
    [Abstract] [Full Text] [Related]

  • 14. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov 28; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 15. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA, Bernstein R, Chynn KY, Kourides IA.
    J Clin Endocrinol Metab; 1992 Mar 28; 74(3):690-4. PubMed ID: 1740506
    [Abstract] [Full Text] [Related]

  • 16. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T, Astorga R, Catalá M, Spanish Multicentre Lanreotide Study Group on Acromegaly.
    Clin Endocrinol (Oxf); 2003 Apr 28; 58(4):471-81. PubMed ID: 12641631
    [Abstract] [Full Text] [Related]

  • 17. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
    Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P.
    Clin Endocrinol (Oxf); 2005 Feb 28; 62(2):176-81. PubMed ID: 15670193
    [Abstract] [Full Text] [Related]

  • 18. [Thyrotropin-secreting pituitary adenomas].
    Caron P.
    Presse Med; 2009 Jan 28; 38(1):107-11. PubMed ID: 18980829
    [Abstract] [Full Text] [Related]

  • 19. Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases.
    Hubalewska-Hola A, Fröss K, Kostecka-Matyja M, Sowa-Staszczak A, Szybiński Z, Huszno B, Ptak M.
    Przegl Lek; 2003 Jan 28; 60(11):768-71. PubMed ID: 15058054
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F.
    Horm Metab Res; 2001 Oct 28; 33(10):618-24. PubMed ID: 11607883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.